Welcome to our dedicated page for Neurogene news (Ticker: NGNE), a resource for investors and traders seeking the latest updates and insights on Neurogene stock.
Neurogene Inc. develops genetic medicines for rare neurological diseases, with recurring updates centered on NGN-401, its investigational AAV9 gene therapy for Rett syndrome. Company news covers the EXACT™ transgene regulation technology, intracerebroventricular delivery for CNS-targeted gene therapy, clinical data from NGN-401 studies, and regulatory designations granted by U.S., European, and U.K. agencies.
Other recurring Neurogene developments include financial results, corporate presentations, scientific conference participation, board and executive appointments, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). The company also identifies NGN-101 as a conventional gene therapy development candidate for CLN5 Batten disease.
Neurogene (Nasdaq: NGNE) granted non-qualified stock options to purchase an aggregate of 96,450 shares of common stock to six new employees under its 2025 Inducement Plan, effective July 6, 2026.
The options have an exercise price equal to the Grant Date closing price and vest over four years, subject to continued employment.
Neurogene (Nasdaq: NGNE) priced a public offering of 3,500,000 common shares at $30.00 each and pre-funded warrants for up to 666,666 shares at $29.999999 per warrant. Expected gross proceeds are about $125 million before fees. Closing is expected on July 2, 2026, with underwriters holding a 30-day option to buy up to 624,999 additional shares.
Neurogene (Nasdaq: NGNE) began a proposed public offering of common stock and, for certain investors, pre-funded warrants. Underwriters are expected to receive a 30-day option to buy more shares. All securities are offered by Neurogene, with proceeds planned for NGN-401 clinical development, pre-commercial activities, and general corporate purposes.
Neurogene (Nasdaq: NGNE) reported updated long-term Phase 1/2 data for NGN-401 gene therapy in females with Rett syndrome (N=10, 12–30 months follow-up). Participants gained 47 total developmental milestones (mean 4.7), with 100% improving on CGI-I and gaining ≥1 milestone, and no milestone loss observed.
Milestone gains occurred in a progressive, developmentally ordered sequence, with median time to first improvement of 2 months and statistically significant changes on RSGMS and RSHFS (p<0.001). At the 1E15 vg dose (N=35), NGN-401 remains generally well-tolerated, with only Grade 1–2 treatment-related adverse events and no treatment-related SAEs or DLTs reported. Dosing is complete in the Embolden registrational trial, with topline data expected in 2H 2027.
Neurogene (Nasdaq: NGNE) completed dosing in the Embolden™ registrational trial of NGN-401, a one-time gene therapy for Rett syndrome, dosing 25 participants versus an initial target of 20 and a pre-specified ITT population of up to 24.
NGN-401 at the 1E15 vg dose (n=35) has been generally well-tolerated with no hemophagocytic lymphohistiocytosis (HLH) reported. Primary analysis for a planned BLA will occur after 24 participants complete 12 months of follow-up, with topline data expected in 2H 2027. Updated Phase 1/2 interim data are planned for mid-2026.
Neurogene (Nasdaq: NGNE) approved inducement grants of non-qualified stock options covering 17,045 shares of common stock for two new employees under its 2025 Inducement Plan, effective June 1, 2026.
The options have an exercise price equal to the grant-date closing price and vest over four years.
Neurogene (Nasdaq: NGNE) reported first quarter 2026 results and clinical progress for NGN-401 in Rett syndrome.
About 90% of Embolden™ trial participants are dosed, NGN-401 at 1E15 vg has been generally well-tolerated with no HLH cases reported, and cash of $243.2 million is expected to fund operations into Q1 2028.
Neurogene (Nasdaq: NGNE) presented data at the ASGCT meeting supporting intracerebroventricular (ICV) delivery as a routine method for CNS-targeted gene therapies, including NGN-401 for Rett syndrome.
Preclinical and Phase 1/2 data showed broad brain biodistribution, functional gains in pediatric participants, and generally well-tolerated ICV administration.
Neurogene (Nasdaq: NGNE) announced inducement option grants under Nasdaq Listing Rule 5635(c)(4) dated May 5, 2026. The Compensation Committee approved non-qualified options to purchase an aggregate of 122,565 shares, including 120,000 shares issued to new Chief Commercial Officer Christy Shafer.
The awards were granted under the 2025 Inducement Plan, use the closing price on the grant date as the exercise price, and vest over four years with a vesting commencement date of April 20, 2026 for Ms. Shafer.
Neurogene (NASDAQ: NGNE) will present at ASGCT May 11-15, 2026 on intracerebroventricular (ICV) delivery as a deliberate neurosurgical route to maximize CNS gene therapy biodistribution.
Poster on May 12 (5:00–6:30 p.m. ET) will show preclinical data where ICV gave greater brain biodistribution than intrathecal‑lumbar, and clinical Phase 1/2 results reporting durable multidomain developmental gains and a safety profile at the 1E15 vg dose supporting advancement to the Embolden registrational trial.